학술논문
A Single Bout of Exercise Enhances the Efficacy of Rituximab Against Autologous Chronic Lymphocytic Leukaemia B Cells Ex VivoBy Transiently Increasing Natural Killer Cell Frequency in Blood, and Simultaneously Mobilises CD5 +CD19 +CD20 +B Cells into Blood
Document Type
Article
Author
Collier-Bain, Harrison D; Emery, Annabelle; Causer, Adam J; Brown, Frankie F; Oliver, Rebecca; Dutton, David; Crowe, Josephine; Augustine, Daniel; Graby, John; Leach, Shoji; Eddy, Rachel; Rothschild Rodriguez, Daniela; Gray, Juliet C; Cragg, Mark S; Cleary, Kirstie L; Moore, Sally; Murray, James; Turner, James E; Campbell, John P
Source
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p1179-1179, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Chronic Lymphocytic Leukaemia (CLL) is characterised by the proliferation and accumulation of clonal B cells (B-CLL cells) and is often treated with anti-CD20 monoclonal antibody immunotherapies, including rituximab. One of the mechanism-of-action of rituximab is antibody-dependent cellular cytotoxicity (ADCC) which occurs when natural killer (NK) cells detect rituximab bound to CD20 +target cells. Rituximab often fails to induce stringent disease eradication, due in part to the diffuse distribution of clonal cells across multiple lymphoid and non-lymphoid tissues where NK cell frequency can be low. It is well established that an individual bout of aerobic exercise induces a transient relocation of lymphocytes - including NK cells and B cells - into peripheral blood. We hypothesised that this exercise-induced lymphocytosis could be harnessed to enhance the efficacy of rituximab in CLL by relocating both target and effector cells together with rituximab into blood.